Although high dose of IL-2 has been used for immunotherapy against metastatic cancer (128), low-dose of IL-2, however, preferentially stimulates Tregs and has shown a great potential of success in Treg-based immunosuppressive strategies against autoimmune and inflammatory diseases (129). Here, IL2 is linked to metastatic malignant neoplasm.